ライフサイエンスコーパス: polyarginine

1 c TAT, different TAT variants, Antp, MTS and polyarginine.

2 as mimicked by the CaR agonists spermine and polyarginine.

3 ) molecular clone was effectively blocked by polyarginine.

4 ion reactions were faster in the presence of polyarginine.

5 cence polarization signal in the presence of polyarginine.

6 igher in the presence than in the absence of polyarginine.

7 ze the transfer of ADP-ribose from NAD(+) to polyarginine.

8 is some 50% larger with polylysine than with polyarginine.

9 possess inhibitory potency almost equal to L-polyarginines.

10 to 140% of the control in the presence of l-polyarginines.

11 Using five SPPs (SPACE peptide, TD-1, polyarginine, a dermis-localizing peptide and a skin pen

12 evidence indicate that HvnA and HvnB mediate polyarginine ADP-ribosylation not by ARTase activity, bu

13 performing the reactions in the presence of polyarginine and continuously measuring the fluorescence

14 We have prepared vesicles composed of polyarginine and polyleucine segments that are stable in

15 ptides with cationic polyamino acids such as polyarginine and polylysine by fluorescence polarization

16 A previously proposed model for binding of polyarginine and protamine to DNA provides a convenient

17 Three SPPs (SPACE, Polyarginine and TD-1) significantly enhanced CsA penetr

18 cant permeation enhancing ability than other polyarginines and TAT peptides.

19 inhibited by CK2 effectors such as heparin, polyarginine, and histone H1, but was not affected by th

20 tial reading frames, generating polyproline, polyarginine, and polyalanine proteins, respectively.

21 ed cationic sequence derived from HIV Tat or polyarginine Arg8, and equals that of hydrocarbon-staple

22 Cellular association of polyarginine-based, cell-penetrating peptides (CPPs) is

23 and HvnB catalyzed ribosylation of not only polyarginine but also polylysine and polyhistidine, and

24 ine, but not asparagine, within a stretch of polyarginine can mediate high-affinity binding.

25 esent study was to investigate the effect of polyarginine chain length on topical delivery of surface

26 artificial cerebrospinal fluid (aCSF) using polyarginine-coated nanodiamonds (PA-coated NDs) as affi

27 oxic to the cells than the corresponding PNA-polyarginine conjugate.

28 yarginine peptides showed that inhibition by polyarginine-containing peptides appeared to depend on t

29 Polyarginine-containing peptides represent potent inhibi

30 Here, we tested polyarginine for inhibition of productive human immunode

31 caused by mutations in KRT1, showing that a polyarginine frameshift in the keratin-1 tail can also c

32 -Arg-Arg-Arg-Arg-Arg or longer iterations of polyarginine have been shown to be competitive inhibitor

33 Polycations such as polylysine, polyarginine, histone H1, histones H2A-H2B, and protamin

34 We found that polyarginine inhibited significantly human immunodeficie

35 Polyarginine insertions in place of residues 24 to 60 th

36 The therapeutic use of D-polyarginines is especially interesting because they are

37 Positively charged peptides of polyarginine mimicked the effect of apoE-rich HDL in red

38 everal CPPs in prostate cancer cell lines, a polyarginine peptide (R11) seemed to be the best deliver

39 r of alpha-syn aggregation (ASID), using the polyarginine peptide delivery system.

40 dentity of the cationic amino acid, with the polyarginine peptide giving the most favourable Delta G

41 ds are capable of mediating the transport of polyarginine peptides across membranes.

42 ort that the cytosolic penetration of linear polyarginine peptides is dependent on the oxidation stat

43 Structure-function analyses of polyarginine peptides showed that inhibition by polyargi

44 sidechain binding enthalpies (polyhistidine, polyarginine, polylysine), weighted by numbers of such c

45 ng a fluorogenic assay, we demonstrated that polyarginine potently inhibited substrate-specific prote

46 ) values of five macromolecules: polylysine, polyarginine, protamine, low-density lipoprotein (LDL),

47 ting human immunodeficiency virus-1 and that polyarginine represents a lead example of such inhibitor

48 Here, we utilized a polyarginine-rich, cell-permeable peptide that represent

49 n pairing influences protein stability using polyarginine salts as a model system.

50 kable feature of these materials is that the polyarginine segments both direct structure for vesicle

51 However, polyarginine substitutions expanded the RNA binding spec

52 cation studies showed that the most potent D-polyarginine tested was nona-D-arginine (D9R) amide with

53 PC2 was not inhibited by any polyarginine tested; indeed, PC2 showed an increase in a

54 d to determine the important elements within polyarginines that contribute to effective inhibition.

55 ific, as indicated by lack of effects by the polyarginine vehicle alone or a scrambled sequence of th

56 Polyarginine was found to have no effect on the rate of

57 tly, a series of non-amidated and acetylated polyarginines was synthesized.

58 zymes, the reaction rates in the presence of polyarginine were found to be sensitive to the presence